RBC Capital upgrades Arxis stock rating on M&A activity, pricing

Arxis, Inc. (ARXS) completed the acquisition of Omnetics Connector Corporation for approximately $770 million, issuing 13.35 million Class A shares. The deal is part of Arxis's roll-up strategy, with Omnetics joining its Electronic Components segment. The company's Q2 revenue grew 25% to $500.7 million, with adjusted EBITDA up 38% to $211.5 million. The acquisition's valuation is based on estimated fiscal-2027 adjusted EBITDA, raising questions about its disciplined underwriting.

Arxis, Inc. (NASDAQ: ARXS) said it completed its acquisition of Omnetics Connector Corporation. The deal was based on an agreed enterprise value of about $770 million, with customary closing adjustments. Arxis issued 13,351,964 shares at closing to Omnetics shareholders, about 3.1% of total common stock, subject to lockups. The combined purchase price multiple with a prior MagCanica deal is about 12x FY27 estimated adjusted EBITDA.

Arxis, Inc. (ARXS) filed an SEC Form 8-K — Completion of Acquisition or Disposition of Assets. Arxis Completes the Acquisition of Omnetics Connector Corporation BLOOMFIELD, Conn., August 18, 2026 — Arxis, Inc. (NASDAQ: ARXS) (the “Company” or “Arxis”), a publicly-traded industrial compounder formed in partnership with Arcline Investment Management (“Arcline”), today announ

Q: Can you provide financials for the Omnetics and Mechanica acquisitions? How did the partnership with Arcline help you win the competitive process for Omnetics? A: (Kevin Parhamas, President and CEO) We are not giving specific numbers, but across the three deals (Blue Line, Mechanica, and Omnetics), they represent small, medium, and large acquisitions. We do not discriminate by size.

Arxis, Inc. (ARXS) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Arxis Reports Second Quarter 2026 Results; Raises Full-Year 2026 Guidance BLOOMFIELD, Conn., July 29, 2026 – Arxis, Inc. (NASDAQ: ARXS) (the “Company” or “Arxis”), a leading designer and manufacturer of proprietary, mission-critical electronic and mechanical engineer

Daiichi Sankyo (4568.TS), AstraZeneca (AZN), and Summit Therapeutics (SMMT) will collaborate on clinical trials to evaluate Datroway (datopotamab deruxtecan) with ivonescimab for multiple solid tumors, starting with a Phase 3 study for triple-negative breast cancer. Datroway is an approved ADC, while ivonescimab is a novel bispecific antibody. Each company will contribute its medicine and share trial costs. SMMT's stock closed at $16.69, down 1.30%.